These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 31391288)

  • 41. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
    Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
    Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.
    Akbari MR; Zhang S; Cragun D; Lee JH; Coppola D; McLaughlin J; Risch HA; Rosen B; Shaw P; Sellers TA; Schildkraut J; Narod SA; Pal T
    Fam Cancer; 2017 Jul; 16(3):351-355. PubMed ID: 28176205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunohistochemical Analysis of Mismatch Repair Gene Proteins in Early Gastric Cancer Based on Microsatellite Status.
    Sugimoto R; Endo M; Osakabe M; Toya Y; Yanagawa N; Matsumoto T; Sugai T
    Digestion; 2021; 102(5):691-700. PubMed ID: 33053554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies Lynch syndrome patients.
    Brand RE; Dudley B; Karloski E; Das R; Fuhrer K; Pai RK; Pai RK
    Fam Cancer; 2020 Apr; 19(2):169-175. PubMed ID: 31997046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.
    Kastrinos F; Steyerberg EW; Balmaña J; Mercado R; Gallinger S; Haile R; Casey G; Hopper JL; LeMarchand L; Lindor NM; Newcomb PA; Thibodeau SN; Syngal S;
    Gut; 2013 Feb; 62(2):272-9. PubMed ID: 22345660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rare germline variants in pancreatic cancer and multiple primary cancers: an autopsy study.
    Fujitani H; Eguchi H; Kochi Y; Arai T; Muramatsu M; Okazaki Y
    Eur J Cancer Prev; 2023 May; 32(3):286-297. PubMed ID: 36896836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.
    Dominguez-Valentin M; Sampson JR; Seppälä TT; Ten Broeke SW; Plazzer JP; Nakken S; Engel C; Aretz S; Jenkins MA; Sunde L; Bernstein I; Capella G; Balaguer F; Thomas H; Evans DG; Burn J; Greenblatt M; Hovig E; de Vos Tot Nederveen Cappel WH; Sijmons RH; Bertario L; Tibiletti MG; Cavestro GM; Lindblom A; Della Valle A; Lopez-Köstner F; Gluck N; Katz LH; Heinimann K; Vaccaro CA; Büttner R; Görgens H; Holinski-Feder E; Morak M; Holzapfel S; Hüneburg R; Knebel Doeberitz MV; Loeffler M; Rahner N; Schackert HK; Steinke-Lange V; Schmiegel W; Vangala D; Pylvänäinen K; Renkonen-Sinisalo L; Hopper JL; Win AK; Haile RW; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Wadt K; Therkildsen C; Okkels H; Ketabi Z; Moreira L; Sánchez A; Serra-Burriel M; Pineda M; Navarro M; Blanco I; Green K; Lalloo F; Crosbie EJ; Hill J; Denton OG; Frayling IM; Rødland EA; Vasen H; Mints M; Neffa F; Esperon P; Alvarez K; Kariv R; Rosner G; Pinero TA; Gonzalez ML; Kalfayan P; Tjandra D; Winship IM; Macrae F; Möslein G; Mecklin JP; Nielsen M; Møller P
    Genet Med; 2020 Jan; 22(1):15-25. PubMed ID: 31337882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mismatch repair gene pathogenic germline variants in a population-based cohort of breast cancer.
    Nguyen-Dumont T; Steen JA; Winship I; Park DJ; Pope BJ; Hammet F; Mahmoodi M; Tsimiklis H; Theys D; Clendenning M; Giles GG; Hopper JL; Southey MC
    Fam Cancer; 2020 Jul; 19(3):197-202. PubMed ID: 32060697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome.
    Tamura K; Kaneda M; Futagawa M; Takeshita M; Kim S; Nakama M; Kawashita N; Tatsumi-Miyajima J
    Int J Clin Oncol; 2019 Sep; 24(9):999-1011. PubMed ID: 31273487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.